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Abstract  
 
New psychoactive substances (NPS) with amphetamine-, aminoindan-, and 
benzofuran basic chemical structures have recently emerged for recreational drug 
use. Detailed information about their psychotropic effects and health risks is often 
limited. At the same time, it emerged that the pharmacological profiles of these NPS 
resemble those of amphetamine or MDMA. Amphetamine-like NPS induce 
psychostimulation and euphoria mediated predominantly by norepinephrine (NE)- and 
dopamine (DA) transporter (NET and DAT) inhibition and transporter-mediated 
release of NE and DA, thus, showing a more catecholamine-selective profile. MDMA-
like NPS frequently induce well-being, empathy, and prosocial effects and have only 
moderate psychostimulant properties. These MDMA-like substances primarily act by 
inhibiting the serotonin (5-HT) transporter (SERT) and NET, also inducing 5-HT and 
NE release. Monoamine receptor interactions vary considerably among amphetamine- 
and MDMA-like NPS. Clinically, amphetamine- and MDMA-like NPS can induce 
sympathomimetic toxicity. The aim of this chapter is to review the state of knowledge 
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regarding these substances with a focus on the description of the in vitro 
pharmacology of selected amphetamine- and MDMA-like NPS. In addition, it is aimed 
to provide links between pharmacological profiles and in vivo effects and toxicity, 
which leads to the conclusion that abuse liability for amphetamine-like NPS may be 
higher than for MDMA-like NPS, but that the risk for developing the life-threatening 
serotonin syndrome may be increased for MDMA-like NPS.  
 
Keywords 
Aminoindans; amphetamine, benzofurans; DAT; dopamine; 4-fluoroamphetamine; 4-
FA; 5-IT; NET; noradrenaline; NPS; MDMA; monoamines; release; serotonin; SERT; 
uptake 
 
 
 
Acronyms of the Discussed New Psychoactive Substances (NPS) 
 
2-AI 2-Aminoindane 
 
3-MMC  3-Methyl-N-methylcathinone 
4-APB 4-(2-Aminopropyl)benzofuran 
 
5-APB 5-(2-Aminopropyl)benzofuran 
 
6-APB 6-(2-Aminopropyl)benzofuran 
 
7-APB  7-(2-Aminopropyl)benzofuran 
5-APDB 5-(2-Aminopropyl)-2,3-dihydrobenzofuran 
 
6-APDB 6-(2-Aminopropyl)-2,3-dihydrobenzofuran 
 
5-EAPB 5-(2-Ethylaminopropyl)benzofuran 
 
4-FA 4-Fluoroamphetamine 
 
5-IAI 5-Iodoaminoindan 
 
5-IT, 5-API 5-(2-Aminopropyl)indole 
 
4-MA 4-Methylamphetamine 
 
5-MAPDB 1-(2,3-Dihydrobenzofuran-5-yl)-N-methylpropan-2-amine 
 
MBDB 3,4-Methylenedioxyphenyl-N-methyl-2-butanamine 
 
MDA 3,4-Methylenedioxyamphetamine 
 
MDAI  3,4-Methylenedioxyaminoindan 
MDEA 3,4-Methylenedioxy-N-ethylamphetamine 
 
MMAI 5-Methoxy-6-methyl-2-aminoindan 
 
4-MTA 4-Methylthioamphetamine 
 
PMA para-Methoxyamphetamine 
 
PMMA para-Methoxymethamphetamine 
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1. Introduction 
 
Amphetamine and its derivative 3,4-methylenedioxymethamphetamine (MDMA) are 
substances that have been abused for decades. Amphetamine, and alternatively 
methamphetamine are typically sold under the street name “speed”, and MDMA is the 
substance typically associated with “ecstasy” pills. Although MDMA is a 3,4-
methylenedioxy derivative of amphetamine, the subjective effects as well as the 
pharmacological profiles of MDMA and amphetamine are distinct. Psychostimulation 
and euphoria are commonly described acute subjective effects of amphetamine 
consumption (Dolder et al. 2017). MDMA is the prototypical 
entactogenic/empathogenic drug (Nichols 1986) and induces fewer psychostimulant 
effects than amphetamine (Bershad et al. 2016). Enhancement of feelings of love, 
happiness, and closeness to others are typical entactogenic effects (Hysek et al. 
2014a; Hysek et al. 2014b; Liechti et al. 2001). Amphetamine and MDMA act on 
monoamine re-uptake transporters (Simmler et al. 2013; Verrico et al. 2007). By 
blocking the serotonin (5-HT), dopamine (DA), and norepinephrine (NE) transporters 
(SERT, DAT, and NET, respectively), re-uptake of the respective neurotransmitters is 
prevented, causing increased neurotransmitter concentrations in the synaptic cleft 
(Kehr et al. 2011; Torres et al. 2003). Amphetamine derivatives typically also induce 
transporter-mediated release of neurotransmitters (Blakely et al. 2005; Hysek et al. 
2012c). Since the neurotransmitters 5-HT, DA, and NE are differentially involved in 
modulating behavior and subjective effects, distinct pharmacological profiles of drugs 
of abuse can be linked to specific psychotropic effects and intoxication (Dolder et al. 
2017; Liechti 2015; Schmid et al. 2014). As such, amphetamine with preference for 
human DAT and NET is experienced differently than MDMA, which, in contrast, 
preferentially acts at human SERT and NET vs. DAT (Simmler et al. 2013).  
 The chemical diversity found among substances commonly referred to as new 
psychoactive substances (NPS) is quite pronounced. Over 600 different NPS have 
emerged on the illicit drug market since the beginning of this century (EMCDDA 2016). 
The pharmacology and psychotropic effects range widely among amphetamine-based 
NPS.  For example, subjective effects induced by NPS based on the amphetamine 
template may range from hallucinogenic via entactogenic to stimulant properties 
predominantly depending on the nature and location of substituents on the phenyl ring 
(Hill and Thomas 2011; Liechti 2015; Zwartsen et al. 2017; Nichols 2017) In addition, 
many amphetamine-based NPS carry a keto group on the ß-position of the carbon 
side chain, thus, giving rise to the cathinone template (Figure 1) (Prosser and Nelson 
2012), Cathinone NPS are discussed in detail in the preceding chapter of this book. 
The present chapter will focus on non-ß-keto NPS that resemble amphetamine and 
MDMA in their pharmacology and subjective effects. The main focus of this chapter is 
the description of the in vitro pharmacology of selected amphetamine- and MDMA-like 
NPS, with the additional aim to provide links between pharmacological profiles and in 
vivo effects and toxicity.  
By using the terms amphetamine- and MDMA-like NPS, we refer mostly to 
pharmacological profiles that are comparable to amphetamine and/or MDMA. Pivotal 
are the relative potencies for inhibition of the human SERT, DAT, and NET. 
Furthermore, characteristic for amphetamine- and MDMA-like substances is that they 
induce transporter-mediated release of monoamines. Release is typical for 
amphetamine and MDMA and distinguishes amphetamine-derivatives from pure 
uptake blockers such as cocaine or the NPS 3,4-methylenedioxypyrovalerone (MDPV; 
Baumann et al. 2013). Our classification of NPS as amphetamine- or MDMA-like is 
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mainly based on the relative activity for uptake inhibition at DAT vs. SERT, referred to 
as DAT/SERT ratio. DAT/SERT ratios are calculated as IC50 value for SERT divided 
by IC50 value for DAT (also as 1/(DAT IC50) divided by 1/(SERT IC50)). DAT/SERT 
ratios can also be calculated for EC50 values for transporter-mediated release 
(Baumann et al. 2012; Marusich et al. 2016). MDMA acts preferentially on SERT, 
reflected in a low DAT/SERT ratio. In contrast, amphetamine acts preferentially on 
DAT, reflected in a high DAT/SERT ratio (Simmler et al. 2013). Below we will discuss 
the pharmacology and psychotropic effects of amphetamine-like and MDMA-like NPS 
separately. 
 
2. MDMA- and amphetamine-like NPS 
 
The amphetamine-derivatives discussed in this chapter are N-ethylamphetamine, 4-
fluoroamphetamine (4-FA), 4-fluoromethamphetamine, 5-(2-aminopropyl)indole (5-IT, 
also known as 5-API), 4-methylamphetamine (4-MA), 3,4-methylenedioxyphenyl-N-
methyl-2-butanamine (MBDB), 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxy-N-ethylamphetamine (MDEA), 4-methylthioamphetamine (4-MTA), 
para-methoxyamphetamine (PMA), and para-methoxymethamphetamine (PMMA). 
Aminoindans discussed are 2-aminoindane (2-AI), 5-iodoaminoindan (5-IAI), 3,4-
methylenedioxyaminoindan (MDAI), and 5-methoxy-6-methyl-2-aminoindan (MMAI). 
Benzofurans discussed are 4-(2-aminopropyl)benzofuran (4-APB), 5-(2-
aminopropyl)benzofuran (5-APB), 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-
APDB), 5-(2-ethylaminopropyl)benzofuran (5-EAPB), 1-(2,3-dihydrobenzofuran-5-yl)-
N-methylpropan-2-amine (5-MAPDB), 6-(2-aminopropyl)benzofuran (6-APB), 6-(2-
aminopropyl)-2,3-dihydrobenzofuran (6-APDB), and 7-(2-aminopropyl)benzofuran (7-
APB). 
If not otherwise noted, we refer to the racemic mixtures of compounds, except 
for D- or (S)-(+)-amphetamine. The isomers of psychoactive drugs with asymmetric 
centers can have different biological activity (Baumann et al. 2007). However, since 
street drugs are produced as racemic mixtures, pharmacological in vitro- or animal 
studies that use the racemic mixtures of the compounds are representative reflections 
of street drug activity. Chemical structures of amphetamine, MDMA and selected NPS 
are shown in Figure 1. Cathinone-derivatives are discussed in the preceding chapter 
of this book, but the structure of cathinone is displayed in Figure 1 to illustrate the ß-
keto substituent typical for cathinone-based NPS. 2-AI forms the basic structure of 
aminoindan-derived NPS, and 5-APB is shown as example for benzofuran NPS.  
 
3. MDMA-like NPS 
 
3.1. Pharmacology of MDMA-like substances 
 
Several specific ring-substituted amphetamine-based NPS that lack the ß-keto 
substituent resemble MDMA in their pharmacological profile. MDMA-like NPS potently 
inhibit the NET and SERT with lower potency for DAT inhibition. Accordingly, their 
DAT/SERT ratio is low, comparable to MDMA, for which our laboratory reported a 
DAT/SERT ratio of 0.08 (Simmler et al. 2013). DAT/SERT ratios for MDMA below 1 
were also reported for release (Eshleman et al. 2017; Marusich et al. 2016; Baumann 
  Simmler and Liechti, HEP chapter 
 6
et al. 2012). As for uptake inhibition (Simmler et al. 2013), these studies also report 
DAT/SERT ratios for amphetamine- or methamphetamine-induced release that are 
>150 times higher than the DAT/SERT ratio of MDMA.  A low DAT/SERT ratio predicts 
MDMA-like subjective effects and a lower dependence potential compared to 
amphetamine (Suyama et al. 2016; Liechti 2015). MDMA-like pharmacological 
properties can be found among benzofurans, aminoindans, and amphetamines.  
MDMA is a prototypical entactogenic/empathogenic drug that retains some 
psychostimulant effects. It increases empathy, sociability, closeness to others, but 
also happiness and self-esteem (Hysek et al. 2014a; Hysek et al. 2014b; Liechti et al. 
2001). Cardiostimulant effects are common and include increased blood pressure, 
increased heart rate, and hyperthermia (Vizeli and Liechti 2017). Bruxism resulting 
from increased muscle tension is also experienced frequently (Cole and Sumnall 
2003). The psychotropic and cardiostimulant effects have been attributed foremost to 
the 5-HT and NE release properties of MDMA (Hysek et al. 2011; Hysek et al. 2012c). 
Concomitant to inducing transporter-mediated 5-HT and NE release, MDMA inhibits 
the re-uptake of the respective neurotransmitters at SERT and NET. MDMA inhibits 
DAT with significant lower potency than it inhibits NET and SERT. Its low DAT/SERT 
ratio (0.08; Simmler et al. 2013) is a representative measure for selectivity of SERT 
over DAT and is used here to compare NPS to MDMA.  
MDMA is also a low-potency partial agonist of the 5-HT2A receptor. Although 
not frequent, mild hallucinogen-like effects of MDMA have been reported, which may 
be attributable to 5-HT2A agonism (Nichols 2004; Liechti et al. 2000). MDA, the active 
metabolite of MDMA (Hysek et al. 2011), shows a 10-fold higher potency for 5-HT2A 
agonism than MDMA (Rickli et al. 2015c). MDA likely contributes to the mode of action 
of MDMA and might contribute to the mild hallucinogenic effects of MDMA.  
Binding affinity of MDMA for adrenergic receptors is low, but since MDMA 
increases NE levels via transporter-mediated NE release and NET uptake inhibition, 
indirectly NE-mediated effects at adrenergic receptors clearly contribute to MDMA 
action  (Hysek et al. 2011). β-Adrenoceptors are involved in MDMA-induced increase 
of heart rate (Hysek et al. 2010). The α1- and β-adrenoceptors have been implicated 
in hyperthermia and drug-induced vasoconstriction (Hysek et al. 2012a). α
 2A-
Adrenocepors are associated with sympathomimetic toxicity and augmented NE 
release (Hysek et al. 2012b). Potent transporter-mediated NE release or even NET 
inhibition seems sufficient to induce cardiostimulant effects mediated through the 
different adrenergic receptors (Hysek et al. 2011). NPS with potent effects at NET thus 
likely induce psychostimulation and sympathomimetic toxicity.  
3.1.1. Serotonergic toxicity 
 
Increased levels of 5-HT can lead to serotonergic toxicity and, in extreme cases, can 
result in precipitation of the serotonin syndrome. Typical symptoms of the serotonin 
syndrome include neuromuscular hyperactivity, clonus, autonomous hyperactivity 
(including hyperthermia), sweating, agitation and confusion (Gillman 2005; Liechti 
2015). MDMA-like drugs typically induce symptoms of serotonergic intoxication, 
potentially leading to a severe serotonin syndrome including hyperthermia but also a 
syndrome of inadequate diuretic hormone (SIADH) resulting in hyponatremia (Simmler 
et al. 2011; Hartung et al. 2002; Holden and Jackson 1996). Hyperthermia, followed 
by life-threatening complications such as rhabdomyolysis, intravascular coagulation, 
and organ failure, is commonly involved in fatal intoxications with psychostimulants 
(Cole and Sumnall 2003). Although hyperthermia is a well-described unwanted effect 
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of MDMA (Liechti 2014), the past has shown that certain psychoactive substances 
induce hyperthermia more readily than MDMA, which has been associated with fatal 
complications. For example, the more traditional substances PMA, PMMA, and 4-MTA 
show a selectivity for SERT over DAT similar to MDMA (Table 1) but the morbidity and 
mortality linked to these particular substances has been observed to be greater and 
more distinct compared to MDMA (Lurie et al. 2012; Vevelstad et al. 2012). Inhibition 
of monoamine oxidase (MAO)-A by PMA, PMMA and 4-MTA (Matsumoto et al. 2014), 
might play a major role in the induction of severe hyperthermia. Increased levels of 
cytosolic 5-HT, resulting from MAO inhibition, might augment drug-induced release of 
5-HT via SERT. The combination of MAO inhibition and 5-HT release, as reported for 
PMA, PMMA and 4-MTA (Matsumoto et al. 2014), is therefore particularly prone to 
induce potentially life-threatening serotonergic intoxication. MAO inhibition has been 
implicated in hyperthermia and the life-threatening serotonin syndrome (Carmo et al. 
2003; Gillman 2005). From the use of selective SERT inhibitors as antidepressants, it 
is well known that the combination of SERT inhibition together with MAO inhibition can 
cause life-threatening serotoninergic intoxication, including hyperthermia. Testing 
NPS for the potential of MAO inhibition might therefore warrant further investigation.  
 
3.1.2. Noradrenergic toxicity 
 
Sympathomimetic toxicity results from increased activation of the NE system, either 
via direct activation of adrenergic receptors or indirectly via receptor activation due to 
increased NE levels (Hysek et al. 2012a; Hysek et al. 2011; Hysek et al. 2010). 
Hyperthermia, hypertension, tachycardia and agitation are typical symptoms of 
stimulant-induced noradrenergic toxicity (Cruickshank and Dyer 2009; Cole and 
Sumnall 2003). Cardiovascular sympathomimetic toxicity is typically associated with 
amphetamine but also occurs following MDMA administration via induction of NE 
release and increases in plasma NE levels. NE-mediated hyperthermia involves 
stimulation of α1- and ß3-adrenoceptors (Sprague et al. 2004; Hysek et al. 2012a). 
Mechanistically, hyperthermia occurs by activation of α1-adrenoceptors via increased 
vasoconstriction, leading to decreased heat dissipation. ß3-Adrenoceptor activation 
causes mitochondrial uncoupling, which increases heat generation (Liechti 2014).  
 
3.2. MDMA-like amphetamine derivatives 
 
The amphetamine-derivatives MBDB, 4-MA, MDEA, 4-MTA, PMA, and PMMA show 
uptake inhibition profiles and DAT/SERT ratios similar to MDMA (Table 1). In vivo drug 
discrimination experiments in rats suggest that PMA, PMMA and 4-MTA show MDMA-
like properties (Dukat et al. 2002; Glennon et al. 2007). However, these substances 
did not substitute for amphetamine in the drug discrimination experiments, which 
predicts that PMA, PMMA and 4-MTA have less stimulant-like properties than MDMA. 
The (S)-(+)-isomer of MDMA showed stimulant properties in rats, reflected in 
hyperlocomotion and substitution for amphetamine in drug discrimination tests 
(Glennon et al. 1988). 4-MTA, PMA and PMMA have been associated with severe 
serotonergic toxicity (Liechti 2015). The combination of MAO inhibition and potent 5-
HT release properties are likely the cause for the high morbidity and mortality reported 
for these substances. Similarly, 4-MA is a potent 5-HT releaser (Baumann et al. 2011) 
and inhibits MAO, and has been associated with fatal intoxications (Blanckaert et al. 
2013). Furthermore, 4-MA is a potent partial agonist at the 5-HT2B receptor (Luethi et 
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al. 2017). This receptor has been implicated in endocardial fibrosis (Roth 2007) but 
whether chronic substance use indeed causes such cardiac complications remains to 
be established. 
MDEA, although equal to MDMA for SERT inhibition potency (Table 1), induces 
hyperthermia in rats less potently than MDMA (Colado et al. 1999). The lower potency 
at NET compared to MDMA (Table 1) might account for this difference, since NE 
release plays a crucial role in the induction of drug-induced hyperthermia (Sprague et 
al. 2004; Hysek et al. 2012a; Liechti 2014). Similarly, MBDB is less potent at NET 
inhibition than MDMA (Table 1; or in rat synaptosomes IC50(MDMA) = 405 nM, IC50(MBDB) 
= 1233 (Johnson et al. 1991)). MBDB is considered to share a range of 
psychopharmacological effects also observed with MDMA and drug discrimination 
studies revealed that MBDB substitutes for MDMA (Aerts et al. 2000). To the best of 
our knowledge, no studies on the effect of MBDB and MDEA on MAO exist to date. 
 
3.3. MDMA-like aminoindans 
 
Aminoindans were originally developed as potential therapeutic bronchodilators, but 
have emerged in the recent years as NPS among recreational drug users, although 
with relatively low prevalence (Brandt et al. 2013; Sainsbury et al. 2011). Among the 
relatively few NPS falling into the aminoindan class, differences in the pharmacological 
profiles have been described. The aminoindans 5-IAI, MDAI, and MMAI show an 
MDMA-like uptake inhibition profile with DAT/SERT ratios smaller or equal to 0.2 
(Table 1). In contrast, 2-aminoindan (2-AI) and N-methyl-2-AI are selective NET 
inhibitors and NE releasers, with 2-AI also releasing DA (Simmler et al. 2014b; Luethi 
et al. 2017). MDAI induces transporter-mediated release of 5-HT and NE, similar to 
MDMA, but, unlike MDMA, MDAI does not induce DA release through the human DAT 
under the conditions investigated (Simmler et al. 2014b; Eshleman et al. 2017). 5-IAI 
causes 5-HT and DA release, but not NE release, although it acts as a potent NET 
inhibitor (Iversen et al. 2013; Simmler et al. 2014b). According to user reports, MDAI 
and 5-IAI cause euphoria and have entactogenic properties (Pinterova et al. 2017). 
Interestingly, MMAI was shown to be selective for SERT over DAT and NET when 
inducing uptake inhibition and transporter-mediated release (Johnson et al. 1991; 
Luethi et al. 2017). The lack of NET activity predicts that MMAI might not be truly 
experienced as MDMA-like, since NE-mediated psychostimulation is likely absent or 
weak in acute MMAI effects, whereas MDMA induces pronounced NE-mediated 
psychostimulation (Hysek et al. 2012a; Hysek et al. 2011; Hysek et al. 2010). The 
selective serotonergic activity could imply a high risk for serotonin syndrome, similar 
to 4-MTA. However, unlike 4-MTA, MMAI does not significantly inhibit MAO (Scorza 
et al. 1999), which might be relevant when considering the potential for severe adverse 
effects.  
Some aminoindans were developed as potential non-neurotoxic alternatives for 
MDMA. MDAI was reported to substitute for MDMA, but not LSD, in drug discrimination 
studies in rats. However, in contrast to MDMA, MDAI did not cause 5-HT depletion 
(Nichols et al. 1990). Similarly, no indication for 5-HT toxicity was found for 5-IAI 
(Nichols et al. 1991). Non-neurotoxic effects of MDAI and 5-IAI suggested that these 
aminoindans might display a safer risk profile compared to MDMA but recent animal 
studies indicated that MDAI can induce potentially life-threatening toxicity related to 
the serotonin syndrome (Gatch et al. 2016; Palenicek et al. 2016). Three fatal 
intoxications involving MDAI and other substances have been described and from 
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ante-mortem information available in one case, the involvement of serotonin toxicity 
was considered likely (Corkery et al. 2013).  
The receptor interaction profiles of MDMA-like aminoindans show that 5-IAI 
exhibits nanomolar affinity at the 5-HT1A-, 5-HT2A- (Simmler et al. 2014b) and the 5-
HT2B receptors (Iversen et al. 2013). Furthermore, affinity (Ki = 1.2 µM) for 5-IAI was 
also observed at the 5-HT2C receptor (Simmler et al. 2014b). This is in contrast to 
MDAI, which did not exhibit affinity to these 5-HT receptors, and to MMAI, which only 
had activity in the micromolar range (Luethi et al. 2017).  
 
3.4. MDMA-like benzofurans 
 
The pharmacology and toxicology of benzofurans is relatively poorly explored to date, 
but fatal, analytically confirmed intoxication with the benzofuran 5-APB alone or in 
combination with 3-MMC have been reported (Adamowicz et al. 2014; McIntyre et al. 
2015). Benzofurans were described by users as substances inducing entactogenic 
and stimulant effects, but also sympathomimetic toxicity, including hyperthermia 
(Welter-Luedeke and Maurer 2016). In drug discrimination studies in rats, the 2,3-
dihydrobenzofurans 5-APDB and 6-APDB substituted for MDMA-like entactogens, but 
not for amphetamine (Monte et al. 1993).  
Many benzofurans show MDMA-like pharmacological profiles. Rickli et al. 
(Rickli et al. 2015b) have characterized a set of benzofurans, which were all potent 
NET inhibitors and showed DAT/SERT ratios < 1 (Table 1). 5-APDB, 5-MAPDB, 5-
APB, and 6-APDB showed high selectivity for SERT over DAT inhibition with 
DAT/SERT ratios of 0.01-0.07. 5-EAPB and 6-APB have DAT/SERT ratios of 0.15 and 
0.29, respectively. The least selective compounds for SERT over DAT were 4-APB 
and 7-APB with DAT/SERT ratios of 0.46 and 0.65. All benzofurans characterized in 
this study induced transporter-mediated release of one, two, or all three monoamines.  
Interestingly, most benzofurans were partial agonists at the 5-HT2A and the 5-
HT2B receptors. 5-HT2A agonism of benzofurans is comparable to MDMA (activation 
potency of 6 µM and 55% efficacy), but MDMA does not have functional activity at the 
5-HT2B receptor (Rickli et al. 2015b). Since activation of the 5-HT2B receptor has been 
associated with heart valve fibrosis (Roth 2007), chronic consumption of benzofurans 
might pose a risk for long-term cardiotoxicity (Dawson et al. 2014). 4-APB, 6-APB, 6-
APBP, and 7-APB showed affinity for the α2A-adrenoceptor in the nanomolar range (Ki 
values of 140 – 870 nM; (Rickli et al. 2015b), which might contribute to the 
sympathomimetic toxicity by augmenting vesicular NE release (Hysek et al. 2012b). 
7-APB is a moderately potent human trace amine-associated receptor 1 
(TAAR1) receptor agonist with an EC50 in the nanomolar range (630 nM), similar to 
the endogenous ligands ß-PEA (260 nM) and p-tyramine (990 nM) and more than 10-
fold more potent than other benzofurans (Simmler et al. 2016). The activation of 
human TAAR1 might diminish the effects of psychostimulation and intoxication arising 
from 7-APB effects on monoamine transporters (see 4.1.3. for more details). Affinity 
to mouse and rat TAAR1 has been shown for many psychostimulants, but species 
differences are common (Simmler et al. 2016). For example, 5-IT and 4-MA bind and 
activate TAAR1 in the nanomolar range, but do not activate human TAAR1. 
 
3.5. Conclusions 
 
Although MDMA-like substances have low abuse liability due to their selectivity for 
SERT over DAT, the risk for potentially life-threatening intoxication appears high 
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considering serotonergic toxicity that, for some MDMA-like NPS, might be augmented 
due to inhibition of MAO. Sympathomimetic toxicity arising from NE action is also 
common. The classification into MDMA-like NPS is approximately based on 
DAT/SERT ratios and does not account for subtle differences in the pharmacology of 
NPS, such as receptor interactions or increased prevalence of 5-HT toxicity. 
Consequently, collecting clinical and pre-clinical information for each MDMA-like NPS 
is helpful for contextualizing the clinical features seen in acute toxicity cases.   
 
4. Amphetamine-like NPS 
 
4.1. Pharmacology of amphetamine-like substances 
 
Subjective effects of amphetamine involve psychostimulation, euphoria, and 
increased arousal. Other clinical features include acute cardiotoxicity, such as 
hypertension, increased blood pressure, heart rate, and body temperature (Dolder et 
al. 2017). Regular amphetamine consumption bears a considerable risk for abuse and 
dependence. Amphetamine increases DA and NE levels by DAT and NET inhibition 
and induction of transporter-mediated release (Heal et al. 2013). Amphetamine further 
shows moderate affinity for the α2A adrenoceptor and the 5-HT1A receptor (Simmler et 
al. 2013) and is a TAAR1 ligand (Bunzow et al. 2001) with potent full agonist properties 
at the human TAAR1 (Simmler et al. 2016). 
Non-ß-keto NPS described here as amphetamine-like show relatively good 
uptake inhibition potencies at SERT with DAT/SERT ratios between 1 and 6 (Table 1). 
In comparison to amphetamine or methamphetamine, 4-fluoroamphetamine, 4-
fluoromethamphetamine, N-ethylamphetamine, and 5-IT are less selective at DAT and 
NET and rather non-selective for all monoamine transporters, although about 10-fold 
more potent at NET than DAT and SERT. Like amphetamine, these amphetamine-like 
NPS also act as monoamine releasers (Simmler et al. 2014a; Rickli et al. 2015a; Luethi 
et al. 2017).  In contrast, there are several cathinone-derivatives with DAT/SERT ratios 
> 10, such as cathinone, methcathinone, or 3-fluoromethcathinone (Simmler et al. 
2013; Simmler et al. 2014a), which resemble amphetamine more closely in their 
transporter inhibition profile.  
 
4.1.1. Acute dopaminergic toxicity 
 
Induction of rapid increase of DA level in the mesolimbic DA system is a typical acute 
effect of many drugs of abuse (Kehr et al. 2011), including amphetamine and cocaine, 
but also opioids, which have indirect effects onto the DA system (Luscher and Malenka 
2011). Drug-induced increase of DA levels activates the reward system and causes 
euphoria (Heal et al. 2013; Sulzer 2011). Unwanted drug effects such as psychotic 
states and aggression can also be attributed to excessive/chronic stimulation of 
dopaminergic action (Harro 2015). Life-threatening excited delirium syndrome has 
been associated with acute dopaminergic toxicity (Mash et al. 2009).  
 
4.1.2. Abuse liability 
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The dopamine system is crucially involved in plasticity underlying drug dependence 
and compulsive drug use (Luscher and Malenka 2011; Pascoli et al. 2015; Koob and 
Volkow 2016). Substances acting to increase DA levels via DAT inhibition and/or DA 
reverse transport might therefore cause dependence, possibly progressing to 
addiction. However, the 5-HT system can oppose dopaminergic effects (Daw et al. 
2002; Alex and Pehek 2007) and serotonergic properties can lower the abuse liability 
of psychostimulants (Simmler et al. 2017; Suyama et al. 2016; Liechti 2015; Bauer et 
al. 2013; Rothman and Baumann 2006; Wee et al. 2005). Accordingly, the relative 
action at DAT vs. SERT is crucial for assessing abuse liability of psychostimulants 
(Baumann et al. 2012). From a pre-clinical perspective, high DAT/SERT ratios are 
generally considered indicative of a significant potential for abuse and dependence. 
The in vitro selectivity for DAT vs. SERT predicts the DA vs. 5-HT release as measured 
using in vivo microdialysis and also correlates with measures of reward such as 
intracranial self-stimulation thresholds as shown for a series of para-ring-substituted 
cathinones (Suyama et al. 2016). In addition, cathinones with a predominant action on 
the DA system are self-administered more readily than substances with a more 5-HT 
activating profile (Bonano et al. 2014; Schindler et al. 2016; Gannon et al. 2018). 
MDMA shows a relatively low abuse liability and has high selectivity of SERT over 
DAT. In the assays carried out in the authors’ laboratory, the abuse dependence 
liability of cocaine is associated with a DAT/SERT ratio of 3.1 and amphetamine and 
methamphetamine have an even higher DAT/SERT ratio of > 10 (Simmler et al. 2013). 
The amphetamine-like NPS discussed here show DAT/SERT ratios of 1-5. From the 
perspective of these studies, these amphetamine-like NPS might show lower abuse 
liability than amphetamine. However, other factors such as drug kinetics, receptor 
interactions, routes of administration and social context also play important roles for 
the clinical picture. 
 
4.1.3. Activation of TAAR1 
 
TAAR1 is a target of amphetamine and many amphetamine-derivatives. TAAR1 is 
involved in the regulation of DA activity (Bradaia et al. 2009) and activation of TAAR1 
reduces the abuse liability of drugs such as cocaine (Pei et al. 2014; Pei et al. 2015). 
Amphetamine and MDMA induce more pronounced psychostimulant effects in rodents 
not expressing TAAR1 (Lindemann et al. 2008; Di Cara et al. 2011). Psychostimulants, 
which act directly on TAAR1, can therefore induce negative modulation of 
psychotropic effects. TAAR1 activation might have protective effect with respect to 
drug toxicity and abuse liability. However, species differences between the rodent 
TAAR1 and human TAAR1 are frequent (Simmler et al. 2016). MDMA activates rat 
and mouse TAAR1 with low micromolar potencies, but its activation potency for the 
human TAAR1 is very low. Amphetamine, in contrast, activates human TAAR1 with 
an EC50 of 2.8 µM (Simmler et al. 2016). For the present chapter, available evidence 
on the activity of NPS at the human TAAR1are presented.  
 
4.2. 4-Fluoroamphetamine, 4-fluoromethamphetamine and N-
ethylamphetamine 
 
4-FA is a popular NPS and described by users to induce a mixture of amphetamine- 
and MDMA-like effects, which include stimulation, euphoria and empathy (Linsen et 
al. 2015; Hondebrink et al. 2017). Despite the entactogenic properties reported for 4-
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FA, which are typical for MDMA-like substances, 4-FA has been included in this 
section due to its DAT/SERT ratio above a value of 1 (Wee et al. 2005; Rickli et al. 
2015a; Eshleman et al. 2017). 4-FA inhibits monoamine transporters with potencies 
in the rank order NET > DAT > SERT (Table 1, Eshleman et al. 2017). The same rank 
order has also been described for the potency of 4-FA to induce monoamine release 
(EC50 values of 28 nM (NE), 52 nM (DA), and 939 nM (5-HT) (Wee et al. 2005). 
Cardiotoxicity and hyperthermia are typical symptoms of sympathomimetic 
intoxication associated with 4-FA use, and severe headache has been increasingly 
reported (Hondebrink et al. 2017). Cerebral hemorrhage and severe cardiovascular 
toxicity were diagnosed in several cases of severe or fatal intoxications (Wijers et al. 
2017; Hondebrink et al. 2017). 4-FA exhibits moderate affinity for the α2A adrenoceptor 
and shows weak to moderate binding affinity or activation potency at the 5-HT1A-, 5-
HT2A-, 5-HT2B-, and 5-HT2C receptors. 4-FA is also a partial agonist at the human 
TAAR1 (Rickli et al. 2015a).  
 4-Fluoromethamphetamine is less frequently reported, but resembles 4-FA in 
its pharmacological profile at monoamine transporters and receptors (Table 1; Rickli 
et al. 2015a). The in vitro data suggest that clinical effects and toxicity might be similar 
to those reported for 4-FA. N-Ethylamphetamine induces hyperlocomotion in mice 
(Tessel et al. 1975) and substitutes for amphetamine in drug-discrimination tests in 
rhesus monkeys (Woolverton and English 1997), which indicates stimulant-like 
properties of N-ethylamphetamine. Furthermore, N-ethylamphetamine showed 
reinforcing properties in rhesus monkeys (Tessel and Woods 1975). N-
Ethylamphetamine was found to show a comparable uptake inhibition profile as 4-
fluoromethamphetamine (Table 1) and functioned as a releaser of DA, NE, and 5-HT 
(EC50 values of 2.6 µM (NE), 93 µM (DA), and 43 µM (5-HT); Tessel and Rutledge 
1976). N-Ethylamphetamine has moderate binding affinity for the α2A-, 5-HT2A-, and 5-
HT2C-receptors (Simmler et al. 2014a), but does not activate human TAAR1 (Simmler 
et al. 2016). Similar to 4-fluoromethamphetamine, the pharmacological profile for N-
ethylamphetamine predict effects and clinical features to be similar to 4-FA.  
4.3. 5-(2-Aminopropyl)indole (5-IT) 
 
5-IT (5-API) has caused a considerable number of fatal intoxications since its 
emergence in 2012 (EMCDDA 2014). The clinical cases presented with 
sympathomimetic and serotonergic toxicity, including hyperthermia, cardiotoxicity, and 
organ failure (Bäckberg et al. 2014). 5-IT inhibits NET, DAT and SERT and 5-IT 
induces transporter-mediated release of NE, DA and 5-HT (Marusich et al. 2016; 
Luethi et al. 2017). Although 5-IT acts more potently at NET and DAT than at SERT, 
serotonergic toxicity has been implicated in the intoxication cases. In addition, 5-IT 
inhibits MAO-A (Herraiz and Brandt 2014), which can augment the rise of 5-HT levels 
and poses the risk for resulting in the development of the serotonin syndrome. 5-IT 
has affinity for the α1A- and α2A adrenoceptors (Ki of 5.4 and 1.7 µM, respectively; 
(Luethi et al. 2017), which might contribute to sympathomimetic toxicity. 5-IT is also a 
potent partial agonist at 5-HT2A and 5-HT2B receptors (EC50 of 0.5 and 1.5 µM, 
respectively; Luethi et al. 2017), which are important for mediating hallucinogenic 
effects via 5-HT2A activity (Nichols 2004) and, in the long-term use, might result in 
heart valve fibrosis mediated via 5-HT2B activity (Roth 2007).  
 
4.4. 2-Aminoindan 
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The use and reported fatalities of 2-AI are relatively rare (Elliott and Evans 2014), and 
not much more recent information about its in vivo pharmacology and toxicology could 
be identified. It is worth noting that the in vitro pharmacological profile of 2-AI is distinct 
from the MDMA-like aminoindans 5-IAI, MDAI and MMAI (see Section 3.3.). In contrast 
to the MDMA-like aminoindans, 2-AI did not inhibit SERT (Table 1; Simmler et al. 
2014b). 2-AI selectively inhibits NET, also inducing NE release, and at higher 
concentrations, also acts as a DAT inhibitor and releaser (Simmler et al. 2014b). The 
selectivity of 2-AI for NET over DAT at the human transporters implies that it causes 
psychotropic effects that may be distinct from amphetamine, since DA-mediated 
euphoria might be low or absent for 2-AI. However, in rat synaptosomes, 2-AI showed 
DAT and NET inhibition (Horn and Snyder 1972). Amphetamine-like properties of 2-
AI were also indicated behaviourally in rats by induction of hyperlocomotion 
(Mrongovius et al. 1978) and by substitution for amphetamine in drug discrimination 
experiments (Glennon et al. 1984). Sympathomimetic effects of 2-AI can arise from 
increased NE levels due to NET inhibition and NE release, and high-affinity (Ki = 450 
nM) binding of 2-AI to the α2A adrenoceptor (Simmler et al. 2014b) likely contributes to 
the sympathomimetic effect of 2-AI. Interestingly, 2-AI was a full agonist at the human 
TAAR1 with similar potency (EC50 of 1.5 µM) similar to amphetamine (EC50 of 2.8 µM), 
which also has full-agonist properties (Simmler et al. 2016). 
 
4.5. Conclusions  
 
Amphetamine-like NPS preferentially inhibit DAT and NET and act as releasers. The 
NPS discussed here show preference for DAT over SERT inhibition, but with lower 
DAT/SERT ratios than amphetamine. The receptor interaction profiles of 
amphetamine-like NPS vary and might contribute to drug-specific psychotropic effects 
and toxicity. MAO inhibition has been shown for 5-IT and suggests particular risk for 
fatal intoxication.  
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Figure 1: Chemical structures of amphetamine, MDMA and selected NPS.  
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Table 1: Uptake inhibition potencies of MDMA, amphetamine, methamphetamine, and selected MDMA- and amphetamine-
like NPS in alphabetical order. Experiments were conducted in vitro with cultured cells that express the human NET, DAT, or 
SERT. All substances were tested as racemic mixtures except for D-amphetamine.  
 NET DAT SERT 
  
  
IC50 (µM) (95% 
CI) 
IC50 (µM) (95% 
CI) 
IC50 (µM) (95% 
CI) 
DAT/SERT 
ratios Values from 
2-AI 0.54 (0.42-0.69) 58 (4-905)  >100 >1 (3) 
D-Amphetamine 0.094 (0.06-0.14) 1.30 (0.83-2.0) >10 >10 (1) 
4-APB 0.24 (0.2-0.3)  12 (9-16)  5.5 (3.4-8.7)  0.46 (5) 
5-APB 0.16 (0.08-0.3)  6.1 (4-9)  0.29 (0.17-0.5)  0.05 (5) 
6-APB 0.19 (0.1-0.3)  3.3 (2.4-4.5)  0.93 (0.7-1.3)  0.29 (5) 
7-APB 0.27 (0.2-0.3)  20 (16-26)  13 (9-18)  0.65 (5) 
5-APDB 0.29 (0.2-0.5)  49 (33-73)  0.58 (0.4-0.9)  0.01 (5) 
6-APDB 0.56 (0.4-0.8)  33 (25-43)  2.3 (1.4-3.9)  0.07 (5) 
5-EAPB 0.56 (0.4-0.7)  4.9 (3-8)  0.72 (0.5-1.1)  0.15 (5) 
N-Ethylamphetamine 0.20 (0.15-0.27) 5.86 (4.8-7.1) 8.77 (6-13) 1.5 (2) 
4-Fluoroamphetamine 0.20 (0.14-0.28)  3.7 (2.4-5.7)  19 (11-33)  5.1 (4) 
4-Fluoromethamphetamine 0.22 (0.14-0.35) 7.7 (2.5-24) 8.7 (3.8-20) 1.1 (4) 
5-IAI 0.76 (0.60-0.98)  23 (15-35)  2.5 (1.9-3.4)  0.11 (3) 
5-IT 0.04 (0.03-0.06)  0.68 (0.55-0.85)  1.3 (0.9-1.7)  1.9 (6) 
5-MAPDB 0.96 (0.5-1.7)  77 (62-96)  1.2 (0.7-2)  0.02 (5) 
MBDB 2.80 (1.9-4.1) 22 (20-26) 2.04 (1.4-3.0) 0.09 (1) 
MDA 0.42 (0.3-0.6) 20.5 (20.3-20.6) 4.9 (3.5-6.8) 0.24 (5) 
MDAI 0.65 (0.50-0.84)  31 (23-41)  8.3 (3.2-22)  0.2 (3) 
MDEA 1.02 (0.78-1.3) 9.3 (8.0-11) 1.27 (0.93-1.7) 0.14 (1) 
MDMA 0.447 (0.33-0.60) 17 (12-24) 1.36 (1.0-2.0) 0.08 (1) 
D-Methamphetamine 0.064 (0.04-0.09) 1.05 (0.74-1.5) >10 >10 (1) 
4-Methylamphetamine 0.31 (0.24-0.42)  5.6 (4.5-6.9)  0.82 (0.64-1.05)  0.15 (6) 
MMAI 3.6 (2.5-5.3)  193 (167-225)  0.68 (0.50-0.92)  0.004 (6) 
4-MTA 1.52 (1.3-1.9)  22 (15-32)  0.54 (0.37-0.80)  0.02 (2) 
PMA 0.80 (0.50-1.0)  71 (60-83)  2.37 (2.0-2.9)  0.03 (2) 
PMMA 1.20 (0.75-1.8) 49 (18-135) 1.77 (1.1-2.9) 0.04 (2) 
(1) Simmler et al., 2013 (4) Rickli et al., 2015a 
(2) Simmler et al., 2014a (5) Rickli et al., 2015b 
  
(3) Simmler et al., 2014b (6) Luethi et al., 2017 
 
 
 
 
